Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$9.13 - $15.52 $3,652 - $6,208
-400 Reduced 1.56%
25,313 $252,000
Q4 2023

Feb 12, 2024

BUY
$5.09 - $10.79 $3,054 - $6,473
600 Added 2.39%
25,713 $253,000
Q3 2023

Nov 14, 2023

SELL
$6.59 - $15.86 $586 - $1,411
-89 Reduced 0.35%
25,113 $192,000
Q2 2023

Aug 11, 2023

SELL
$4.56 - $9.94 $902 - $1,968
-198 Reduced 0.78%
25,202 $188,000
Q1 2023

May 12, 2023

BUY
$6.42 - $9.64 $1,284 - $1,928
200 Added 0.79%
25,400 $169,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $110,403 - $191,760
14,100 Added 127.03%
25,200 $269,000
Q2 2022

Aug 11, 2022

BUY
$5.04 - $9.26 $55,944 - $102,786
11,100 New
11,100 $90,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.41B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.